Cargando…

Spotlight on PSMA as a new theranostic biomarker for bladder cancer

Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tumedei, Maria Maddalena, Ravaioli, Sara, Matteucci, Federica, Celli, Monica, De Giorgi, Ugo, Gunelli, Roberta, Puccetti, Maurizio, Paganelli, Giovanni, Bravaccini, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105396/ https://www.ncbi.nlm.nih.gov/pubmed/33963223 http://dx.doi.org/10.1038/s41598-021-89160-0

Ejemplares similares

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
por: Bravaccini, Sara, et al.
Publicado: (2018)

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold
por: Maltoni, Roberta, et al.
Publicado: (2020)

Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
por: Cortesi, Michela, et al.
Publicado: (2021)

Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology
por: Ravaioli, Sara, et al.
Publicado: (2016)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Maltoni, Roberta, et al.
Publicado: (2020)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
por: Pirini, Francesca, et al.
Publicado: (2023)

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy
por: Caroli, Paola, et al.
Publicado: (2020)

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
por: Bravaccini, Sara, et al.
Publicado: (2018)

Androgen receptor in breast cancer: The “5W” questions
por: Ravaioli, Sara, et al.
Publicado: (2022)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Radiomics Analysis on [(68)Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial
por: Feliciani, Giacomo, et al.
Publicado: (2022)

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial
por: Bravaccini, Sara, et al.
Publicado: (2020)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2017)

Why the complications of COVID-19 patients differ in elderly and young cancer patients
por: Bravaccini, Sara, et al.
Publicado: (2022)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients
por: Ravaioli, Sara, et al.
Publicado: (2020)

Spotlight on nano-theranostics in South Korea: applications in diagnostics and treatment of diseases
por: Lee, Sangwha, et al.
Publicado: (2015)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

Diagnostic and Prognostic Potential of (18)F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy
por: Celli, Monica, et al.
Publicado: (2021)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8qqr1hdf38f47bh2g2lqmrabev